CSIMarket



Worst Performing Stocks In Biotechnology & Pharmaceuticals Industry 2024 Year To Date



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares declined by -4.59% on average, in Biotechnology & Pharmaceuticals Industry 2024 year to date.

Here are the Worst performing stocks in Biotechnology & Pharmaceuticals Industry.




GILD

$64.9491

$-18.2909 -21.97%
2024 Year to Date


GILD

$64.9491

$-18.2909 -21.97%



Gilead Sciences Inc

Gilead Sciences Inc shares declined -21.97% 2024 year to date.


Gilead Sciences Inc*s business model revolves around researching, developing, and commercializing innovative medicines in various therapeutic areas, with a primary focus on antiviral drugs. They aim to address unmet medical needs and improve the lives of patients worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 80,991.528 mill. $ 27,450.000 mill. $ 458.000 mill. 1,247 mill. 179.33 Y/Y 5.26 %
Market Cap. Revenues TTM Net Income TTM

$ 80,991.528 mill.


$ 27,450.000 mill.


$ 458.000 mill.

Employees Shares Outstanding P/E

14,400


1,247 mill.


179.33

Revenue Growth Income Growth

MRQ Y/Y 5.26 %


MRQ Y/Y - %



BIIB

$231.735

$-35.9750 -13.44%
2024 Year to Date


BIIB

$231.735

$-35.9750 -13.44%



Biogen Inc

Biogen Inc stock declined -13.44% 2024 year to date.


Biogen Inc*s business model revolves around researching, developing, and commercializing therapies for neurological and neurodegenerative diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 33,810.137 mill. $ 9,663.100 mill. $ 1,167.300 mill. 146 mill. 28.97 Y/Y -7.00 %
Market Cap. Revenues TTM Net Income TTM

$ 33,810.137 mill.


$ 9,663.100 mill.


$ 1,167.300 mill.

Employees Shares Outstanding P/E

9,610


146 mill.


28.97

Revenue Growth Income Growth

MRQ Y/Y -7.00 %


MRQ Y/Y 1.50 %



AMGN

$298.39

$1.0000 0.34%
2024 Year to Date


AMGN

$298.39

$1.0000 0.34%



Amgen Inc

Amgen Inc stock increased 0.34% 2024 year to date.


Amgen Inc*s business model is centered around developing, manufacturing, and commercializing innovative biotechnology products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 159,937.040 mill. $ 29,532.000 mill. $ 3,763.000 mill. 536 mill. 42.61 Y/Y 21.98 %
Market Cap. Revenues TTM Net Income TTM

$ 159,937.040 mill.


$ 29,532.000 mill.


$ 3,763.000 mill.

Employees Shares Outstanding P/E

24,200


536 mill.


42.61

Revenue Growth Income Growth

MRQ Y/Y 21.98 %


MRQ Y/Y - %



ARGX

$387

$6.0000 1.57%
2024 Year to Date


ARGX

$387

$6.0000 1.57%



Argenx se

Argenx Se shares improved 1.57% 2024 year to date.


Argenx is a biopharmaceutical company that utilizes its proprietary antibody discovery platform to develop and commercialize transformative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Their business model focuses on discovering and developing novel antibodies, partnering with pharmaceutical companies for clinical development, and retaining rights to commercialize the therapies in specific regions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 22,124.501 mill. $ 2,494.910 mill. $ -295.053 mill. 57 mill. - Y/Y 191.46 %
Market Cap. Revenues TTM Net Income TTM

$ 22,124.501 mill.


$ 2,494.910 mill.


$ -295.053 mill.

Employees Shares Outstanding P/E

-


57 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 191.46 %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com